{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T16:51:52Z","timestamp":1775580712555,"version":"3.50.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"11-12","license":[{"start":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T00:00:00Z","timestamp":1685145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T00:00:00Z","timestamp":1685145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the Zhejiang Medical and Health Science and Technology Plan Project","award":["2022KY868"],"award-info":[{"award-number":["2022KY868"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81770202"],"award-info":[{"award-number":["81770202"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Key Project from Science and Technology Department of Zhejiang Province","award":["2019C03032"],"award-info":[{"award-number":["2019C03032"]}]},{"name":"Pediatric Leukemia Diagnostic and Therapeutic Technology Research Center of Zhejiang Province","award":["JBZX-201904"],"award-info":[{"award-number":["JBZX-201904"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Apoptosis"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s10495-023-01853-1","type":"journal-article","created":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T09:02:32Z","timestamp":1685178152000},"page":"1534-1545","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Exploratory study on the efficacy of bortezomib combining mitoxantrone or CD22-CAR T therapy targeting CD19-negative relapse after CD19-CAR T cell therapy with a simpler cell-line-based model"],"prefix":"10.1007","volume":"28","author":[{"given":"Diandian","family":"Ba","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongzhe","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongrong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongmin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,27]]},"reference":[{"key":"1853_CR1","doi-asserted-by":"publisher","unstructured":"Curran KJ, Margossian SP, Kernan NA et al (2019) Toxicity and response after CD19-specific CAR T-cell therapy in pediatric\/young adult relapsed\/refractory B-ALL.Blood(. 26:2361\u20132368. https:\/\/doi.org\/10.1182\/blood.2019001641","DOI":"10.1182\/blood.2019001641"},{"key":"1853_CR2","doi-asserted-by":"publisher","unstructured":"Fry TJ, Shah NN, Orentas RJ et al (2018) CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.Nat Med. 1:20\u201328. https:\/\/doi.org\/10.1038\/nm.4441","DOI":"10.1038\/nm.4441"},{"key":"1853_CR3","doi-asserted-by":"publisher","unstructured":"Lee DW, Kochenderfer JN, Stetler-Stevenson M et al (2015) T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.Lancet(. 9967:517\u2013528. https:\/\/doi.org\/10.1016\/s0140-6736(14)61403-3","DOI":"10.1016\/s0140-6736(14)61403-3"},{"key":"1853_CR4","doi-asserted-by":"publisher","unstructured":"Gardner R, Wu D, Cherian S et al (2016) Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy.Blood(. 20:2406. https:\/\/doi.org\/10.1182\/blood-2015-08-665547","DOI":"10.1182\/blood-2015-08-665547"},{"key":"1853_CR5","doi-asserted-by":"publisher","unstructured":"Majzner RG (2018) Mackall.Tumor Antigen escape from CAR T-cell Therapy.Cancer Discov. 10:1219\u20131226. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0442","DOI":"10.1158\/2159-8290.CD-18-0442"},{"key":"1853_CR6","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/ajh.26160","volume":"6","author":"S Liu","year":"2021","unstructured":"Liu S, Deng B, Yin Z et al (2021) Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation. Am J Hematol 6:671\u2013679. https:\/\/doi.org\/10.1002\/ajh.26160","journal-title":"Am J Hematol"},{"key":"1853_CR7","doi-asserted-by":"publisher","unstructured":"Guedan S, Delgado.Immobilizing J, Moving Target A (2019) CAR T cells hit CD22.Clin Cancer Res. 17:5188\u20135190. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1649","DOI":"10.1158\/1078-0432.CCR-19-1649"},{"key":"1853_CR8","doi-asserted-by":"publisher","unstructured":"Raponi S, De Propris MS, Intoppa S et al (2011) Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases.Leuk lymphoma. 6:1098\u20131107. https:\/\/doi.org\/10.3109\/10428194.2011.559668","DOI":"10.3109\/10428194.2011.559668"},{"key":"1853_CR9","doi-asserted-by":"publisher","unstructured":"Pan J, Niu Q, Deng B et al (2019) CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia.Leukemia(. 12:2854\u20132866. https:\/\/doi.org\/10.1038\/s41375-019-0488-7","DOI":"10.1038\/s41375-019-0488-7"},{"key":"1853_CR10","doi-asserted-by":"publisher","unstructured":"Fousek K, Watanabe J, Joseph SK et al (2021) CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression.Leukemia(. 1:75\u201389. https:\/\/doi.org\/10.1038\/s41375-020-0792-2","DOI":"10.1038\/s41375-020-0792-2"},{"key":"1853_CR11","doi-asserted-by":"publisher","unstructured":"Martyniszyn A, Krahl AC, Andre MC et al (2017) CD20-CD19 bispecific CAR T cells for the treatment of B-Cell Malignancies.Hum Gene Ther. 12:1147\u20131157. https:\/\/doi.org\/10.1089\/hum.2017.126","DOI":"10.1089\/hum.2017.126"},{"key":"1853_CR12","doi-asserted-by":"publisher","unstructured":"Qin H, Ramakrishna S, Nguyen S et al (2018) Preclinical Development of Bivalent chimeric Antigen Receptors Targeting both CD19 and CD22.Mol Ther Oncolytics. 127\u2013137. https:\/\/doi.org\/10.1016\/j.omto.2018.10.006","DOI":"10.1016\/j.omto.2018.10.006"},{"key":"1853_CR13","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1172\/JCI83416","volume":"8","author":"M Hegde","year":"2016","unstructured":"Hegde M, Mukherjee M, Grada Z et al (2016) Tandem CAR T cells targeting HER2 and IL13Ralpha2 mitigate tumor antigen escape. J Clin Invest 8:3036\u20133052. https:\/\/doi.org\/10.1172\/JCI83416","journal-title":"J Clin Invest"},{"key":"1853_CR14","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1016\/j.leukres.2014.09.018","volume":"12","author":"M Liedtke","year":"2014","unstructured":"Liedtke M, Dunn T, Dinner S et al (2014) Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia. Leuk Res 12:1441\u20131445. https:\/\/doi.org\/10.1016\/j.leukres.2014.09.018","journal-title":"Leuk Res"},{"key":"1853_CR15","doi-asserted-by":"publisher","unstructured":"Mitsiades N, Mitsiades CS, Richardson PG et al (2003) The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications.Blood(. 6:2377\u20132380. https:\/\/doi.org\/10.1182\/blood-2002-06-1768","DOI":"10.1182\/blood-2002-06-1768"},{"key":"1853_CR16","doi-asserted-by":"publisher","unstructured":"Horton TM, Perentesis JP, Gamis AS et al (2014) A phase 2 study of bortezomib combined with either idarubicin\/cytarabine or cytarabine\/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children\u2019s Oncology Group.Pediatr Blood Cancer. 10:1754\u20131760. https:\/\/doi.org\/10.1002\/pbc.25117","DOI":"10.1002\/pbc.25117"},{"key":"1853_CR17","doi-asserted-by":"publisher","unstructured":"Horton TM, Pati D, Plon SE et al (2007) A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children\u2019s Oncology Group study.Clin Cancer Res. 5:1516\u20131522. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-2173","DOI":"10.1158\/1078-0432.CCR-06-2173"},{"key":"1853_CR18","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/bjh.15919","volume":"2","author":"TM Horton","year":"2019","unstructured":"Horton TM, Whitlock JA, Lu X et al (2019) Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: a report from the Children\u2019s Oncology Group. Br J Haematol 2:274\u2013285. https:\/\/doi.org\/10.1111\/bjh.15919","journal-title":"Br J Haematol"},{"key":"1853_CR19","doi-asserted-by":"publisher","unstructured":"La Starza R, Camb\u00f2 B, Pierini A et al (2019) Venetoclax and Bortezomib in Relapsed\/Refractory Early T-Cell Precursor Acute Lymphoblastic Leukemia. https:\/\/doi.org\/10.1200\/po.19.00172. JCO Precis Oncol.(","DOI":"10.1200\/po.19.00172"},{"key":"1853_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0246-1","author":"D Schneider","year":"2017","unstructured":"Schneider D, Xiong Y, Wu D et al (2017) A tandem CD19\/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines. J Immunother Cancer. https:\/\/doi.org\/10.1186\/s40425-017-0246-1","journal-title":"J Immunother Cancer"},{"key":"1853_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13963","author":"W Schachterle","year":"2017","unstructured":"Schachterle W, Badwe CR, Palikuqi B et al (2017) Sox17 drives functional engraftment of endothelium converted from non-vascular cells. Nat Commun. https:\/\/doi.org\/10.1038\/ncomms13963","journal-title":"Nat Commun"},{"key":"1853_CR22","doi-asserted-by":"publisher","unstructured":"Wang P, Huang Z, Peng Y et al, Circular RNA et al circBNC2 inhibits epithelial cell G2-M arrest to prevent fibrotic maladaptive repair.Nat Commun.(2022)1:6502.doi: https:\/\/doi.org\/10.1038\/s41467-022-34287-5","DOI":"10.1038\/s41467-022-34287-5"},{"key":"1853_CR23","doi-asserted-by":"publisher","unstructured":"Wang Z, Wang Y, Wang S et al Coxsackievirus A6 induces cell cycle arrest in G0\/G1 phase for viral production.Front Cell Infect Microbiol.(2018)279.doi: https:\/\/doi.org\/10.3389\/fcimb.2018.00279","DOI":"10.3389\/fcimb.2018.00279"},{"key":"1853_CR24","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.3748\/wjg.v23.i14.2511","volume":"14","author":"SX Jiang","year":"2017","unstructured":"Jiang SX, Qi B, Yao WJ et al (2017) Berberine displays antitumor activity in esophageal cancer cells in vitro. World J Gastroenterol 14:2511\u20132518. https:\/\/doi.org\/10.3748\/wjg.v23.i14.2511","journal-title":"World J Gastroenterol"},{"key":"1853_CR25","doi-asserted-by":"publisher","unstructured":"Yang F, Zhang J, Zhang X et al (2019) Delayed remission following sequential infusion of humanized CD19- and CD22-modified CAR-T cells in a patient with relapsed\/refractory acute lymphoblastic leukemia and prior exposure to murine-derived CD19-directed CAR-T cells.Onco targets Ther. 2187\u20132191. https:\/\/doi.org\/10.2147\/OTT.S189103","DOI":"10.2147\/OTT.S189103"},{"key":"1853_CR26","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1182\/blood.V128.22.218.218","volume":"22","author":"DW Lee","year":"2016","unstructured":"Lee DW, Stetler-Stevenson M, Yuan CM et al (2016) Long-term outcomes following CD19 CAR T cell therapy for B-ALL are Superior in Patients receiving a Fludarabine\/Cyclophosphamide preparative regimen and Post-CAR hematopoietic. Stem Cell Transplantation Blood 22:218\u2013218. https:\/\/doi.org\/10.1182\/blood.V128.22.218.218","journal-title":"Stem Cell Transplantation Blood"},{"key":"1853_CR27","doi-asserted-by":"publisher","unstructured":"Skorka K, Ostapinska K, Malesa A et al The application of CAR-T cells in Haematological Malignancies.Arch Immunol Ther Exp (Warsz).(2020)6:34.doi: https:\/\/doi.org\/10.1007\/s00005-020-00599-x","DOI":"10.1007\/s00005-020-00599-x"},{"key":"1853_CR28","doi-asserted-by":"publisher","unstructured":"K\u00f6hl U, Arsenieva S, Holzinger A et al (2018) CAR T cells in trials: recent Achievements and Challenges that remain in the production of modified T cells for clinical Applications.Hum Gene Ther. 5:559\u2013568. https:\/\/doi.org\/10.1089\/hum.2017.254","DOI":"10.1089\/hum.2017.254"},{"key":"1853_CR29","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/cpt.1674","volume":"1","author":"SA Holstein","year":"2020","unstructured":"Holstein SA, Lunning MA (2020) .CAR T-Cell therapy in hematologic malignancies: a voyage. Progress Clin Pharmacol Ther 1:112\u2013122. https:\/\/doi.org\/10.1002\/cpt.1674","journal-title":"Progress Clin Pharmacol Ther"},{"key":"1853_CR30","doi-asserted-by":"publisher","unstructured":"Abreu TR, Fonseca NA, Gon\u00e7alves N et al (2020) Current challenges and emerging opportunities of CAR-T cell therapies.J Control Release. 246\u2013261. https:\/\/doi.org\/10.1016\/j.jconrel.2019.12.047","DOI":"10.1016\/j.jconrel.2019.12.047"},{"key":"1853_CR31","doi-asserted-by":"publisher","unstructured":"Shouse G, Danilov AV, Artz A (2022) .CAR T-Cell therapy in the older person: indications and Risks.Curr Oncol Rep. 9:1189\u20131199. https:\/\/doi.org\/10.1007\/s11912-022-01272-6","DOI":"10.1007\/s11912-022-01272-6"},{"key":"1853_CR32","doi-asserted-by":"publisher","unstructured":"Dinner S, Lee D (2014) Liedtke.Current therapy and novel agents for relapsed or refractory acute lymphoblastic leukemia.Leuk lymphoma. 8:1715\u20131724. https:\/\/doi.org\/10.3109\/10428194.2013.856428","DOI":"10.3109\/10428194.2013.856428"},{"key":"1853_CR33","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1111\/bjh.14505","volume":"4","author":"A Bertaina","year":"2017","unstructured":"Bertaina A, Vinti L, Strocchio L et al (2017) The combination of bortezomib with chemotherapy to treat relapsed\/refractory acute lymphoblastic leukaemia of childhood. Br J Haematol 4:629\u2013636. https:\/\/doi.org\/10.1111\/bjh.14505","journal-title":"Br J Haematol"},{"key":"1853_CR34","doi-asserted-by":"publisher","unstructured":"Story JY, Zoine JT, Burnham RE et al (2021) Bortezomib enhances cytotoxicity of ex vivo-expanded gamma delta T cells against acute myeloid leukemia and T-cell acute lymphoblastic leukemia.Cytotherapy(. 1:12\u201324. https:\/\/doi.org\/10.1016\/j.jcyt.2020.09.010","DOI":"10.1016\/j.jcyt.2020.09.010"},{"key":"1853_CR35","doi-asserted-by":"publisher","unstructured":"Yu L, Wei J (2022) Liu.Attacking the PI3K\/Akt\/mTOR signaling pathway for targeted therapeutic treatment in human cancer. Semin Cancer Biol 69\u201394. https:\/\/doi.org\/10.1016\/j.semcancer.2021.06.019","DOI":"10.1016\/j.semcancer.2021.06.019"},{"key":"1853_CR36","doi-asserted-by":"publisher","first-page":"5413","DOI":"10.1002\/jcp.29429","volume":"6","author":"C Evangelisti","year":"2020","unstructured":"Evangelisti C, Chiarini F, Cappellini A et al (2020) Targeting Wnt\/beta-catenin and PI3K\/Akt\/mTOR pathways in T-cell acute lymphoblastic leukemia. J Cell Physiol 6:5413\u20135428. https:\/\/doi.org\/10.1002\/jcp.29429","journal-title":"J Cell Physiol"},{"key":"1853_CR37","doi-asserted-by":"publisher","unstructured":"Spiegel JY, Patel S, Muffly L et al (2021) CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial.Nat Med. 8:1419\u20131431. https:\/\/doi.org\/10.1038\/s41591-021-01436-0","DOI":"10.1038\/s41591-021-01436-0"},{"key":"1853_CR38","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1002\/ijc.32662","volume":"8","author":"J Shi","year":"2020","unstructured":"Shi J, Li Y, Jia R et al (2020) The fidelity of cancer cells in PDX models: characteristics, mechanism and clinical significance. Int J Cancer 8:2078\u20132088. https:\/\/doi.org\/10.1002\/ijc.32662","journal-title":"Int J Cancer"},{"key":"1853_CR39","doi-asserted-by":"publisher","unstructured":"Jung J, Seol HS (2018) Chang.The Generation and Application of patient-derived xenograft model for Cancer Research.Cancer res treat. 1:1\u201310. https:\/\/doi.org\/10.4143\/crt.2017.307","DOI":"10.4143\/crt.2017.307"},{"key":"1853_CR40","doi-asserted-by":"publisher","unstructured":"Invrea F, Rovito R, Torchiaro E et al (2020) Patient-derived xenografts (PDXs) as model systems for human cancer.Curr Opin Biotechnol. 151\u2013156. https:\/\/doi.org\/10.1016\/j.copbio.2020.01.003","DOI":"10.1016\/j.copbio.2020.01.003"},{"key":"1853_CR41","doi-asserted-by":"publisher","unstructured":"Asnani M, Hayer KE, Naqvi AS et al (2020) Retention of CD19 intron 2 contributes to CART-19 resistance in leukemias with subclonal frameshift mutations in CD19.Leukemia(. 4:1202\u20131207. https:\/\/doi.org\/10.1038\/s41375-019-0580-z","DOI":"10.1038\/s41375-019-0580-z"},{"key":"1853_CR42","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","volume":"10","author":"EJ Orlando","year":"2018","unstructured":"Orlando EJ, Han X, Tribouley C et al (2018) Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nat Med 10:1504\u20131506. https:\/\/doi.org\/10.1038\/s41591-018-0146-z","journal-title":"Nat Med"},{"key":"1853_CR43","doi-asserted-by":"publisher","unstructured":"H\u00f6pken UE (2019) Rehm.Targeting the Tumor Microenvironment of Leukemia and Lymphoma.Trends Cancer. 6:351\u2013364. https:\/\/doi.org\/10.1016\/j.trecan.2019.05.001","DOI":"10.1016\/j.trecan.2019.05.001"},{"key":"1853_CR44","doi-asserted-by":"publisher","unstructured":"Zhang X, Zhu L, Zhang H et al CAR-T cell therapy in hematological malignancies: current Opportunities and Challenges.Front Immunol.(2022)927153.doi: https:\/\/doi.org\/10.3389\/fimmu.2022.927153","DOI":"10.3389\/fimmu.2022.927153"}],"container-title":["Apoptosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-023-01853-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10495-023-01853-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-023-01853-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T06:14:53Z","timestamp":1698732893000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10495-023-01853-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,27]]},"references-count":44,"journal-issue":{"issue":"11-12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["1853"],"URL":"https:\/\/doi.org\/10.1007\/s10495-023-01853-1","relation":{},"ISSN":["1360-8185","1573-675X"],"issn-type":[{"value":"1360-8185","type":"print"},{"value":"1573-675X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,27]]},"assertion":[{"value":"2 May 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no conflicts of interests in this work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}